Previous close | 14.09 |
Open | 13.60 |
Bid | 13.89 x 100 |
Ask | 14.00 x 200 |
Day's range | 13.60 - 14.17 |
52-week range | 5.56 - 21.17 |
Volume | |
Avg. volume | 804,701 |
Market cap | 1.097B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.97 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 26.25 |
CAMBRIDGE, Mass., April 12, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purcha
Strategic Progress Amidst Increased Net Loss
CAMBRIDGE, Mass., March 19, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2023.